WS Investor
01 Sep 2026, 15:45
Veeva Introduces Falcon Safety AI Platform to Automate Drug Safety Operations
Veeva Systems (NYSE: VEEV) announced Tuesday Veeva Falcon Safety, a new agentic AI product designed to automate and streamline pharmacovigilance operations for biopharmaceutical companies.
Falcon Safety will support adverse-event intake, case processing and follow-up, with the goal of reducing operating costs and processing times while maintaining regulatory compliance. The product is part of Veeva AI, the company’s portfolio of industry-specific artificial intelligence solutions for life sciences.
Importantly, Falcon Safety will not be limited to customers using Veeva’s own Safety platform. The product is designed to work with any E2B-compliant safety system, including competing platforms such as Oracle Argus and ArisGlobal LifeSphere MultiVigilance, and across different adverse-event intake channels.
That interoperability could significantly expand Falcon Safety’s addressable market by allowing pharmaceutical companies to adopt Veeva’s AI capabilities without replacing their existing pharmacovigilance infrastructure.
The launch also demonstrates how Veeva is extending AI deeper into specialized, highly regulated life-sciences workflows, where automation can potentially generate meaningful productivity improvements. Falcon Safety is scheduled to become available to early adopters in November 2026.
Veeva Systems (NYSE: VEEV) announced Tuesday Veeva Falcon Safety, a new agentic AI product designed to automate and streamline pharmacovigilance operations for biopharmaceutical companies.
Falcon Safety will support adverse-event intake, case processing and follow-up, with the goal of reducing operating costs and processing times while maintaining regulatory compliance. The product is part of Veeva AI, the company’s portfolio of industry-specific artificial intelligence solutions for life sciences.
Importantly, Falcon Safety will not be limited to customers using Veeva’s own Safety platform. The product is designed to work with any E2B-compliant safety system, including competing platforms such as Oracle Argus and ArisGlobal LifeSphere MultiVigilance, and across different adverse-event intake channels.
That interoperability could significantly expand Falcon Safety’s addressable market by allowing pharmaceutical companies to adopt Veeva’s AI capabilities without replacing their existing pharmacovigilance infrastructure.
The launch also demonstrates how Veeva is extending AI deeper into specialized, highly regulated life-sciences workflows, where automation can potentially generate meaningful productivity improvements. Falcon Safety is scheduled to become available to early adopters in November 2026.
